CDKN1A and colorectal carcinoma: In previous studies, miR-93-5p showed a bidirectional effect in CRC progression, either by inhibiting PD-L1 from weakening CRC cell transfer (11) or by inhibiting cyclin-dependent kinase inhibitor 1A from enhancing the multidrug resistance of CRC cells (26).